AirSculpt Technologies, Inc. (AIRS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

AirSculpt Technologies, Inc. (AIRS) Healthcare & Pipeline Overview

AirSculpt Technologies, Inc. specializes in minimally invasive body contouring through its AirSculpt procedure, offering fat removal and transfer services. Operating in the medical care facilities sector, the company differentiates itself with a proprietary technique and a focus on patient-specific customization, serving a growing market for aesthetic procedures.

What Is the Investment Thesis for AIRS?

AirSculpt Technologies presents a focused investment opportunity within the aesthetic medical services sector. The company's proprietary AirSculpt technology offers a differentiated approach to body contouring, potentially driving revenue growth through increased market penetration. With a gross margin of 63.5%, AirSculpt demonstrates strong pricing power and operational efficiency. Key value drivers include expanding its geographic footprint by opening new centers and increasing brand awareness through targeted marketing efforts. However, the company's negative profit margin of -7.7% raises concerns about profitability and cost management. The high beta of 2.80 indicates significant volatility, reflecting sensitivity to market fluctuations. Successful execution of its expansion strategy and improved cost controls are crucial for realizing the company's growth potential. Investors should closely monitor the company's ability to achieve profitability and manage its operational expenses.

Based on FMP financials and quantitative analysis

AIRS Key Highlights

AirSculpt Technologies operates 19 centers across 15 states as of March 2022, indicating a growing geographic presence.

• The company's gross margin of 63.5% demonstrates strong pricing power and efficient service delivery.
• AirSculpt's proprietary AirSculpt procedure offers a minimally invasive alternative to traditional liposuction, differentiating it in the market.
• The company's market capitalization is $0.12 billion, reflecting its current valuation in the market.
• AirSculpt's beta of 2.80 indicates high volatility compared to the broader market.

Who Are AIRS's Competitors?

AIRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AIRS's Key Strengths?

Proprietary AirSculpt technology.

• Minimally invasive procedure reduces recovery time.
• Customized treatment plans tailored to individual needs.
• Strong brand reputation in body contouring.

What Are AIRS's Weaknesses?

Negative profit margin raises concerns about profitability.

• Limited geographic presence compared to larger competitors.
• High beta indicates significant market volatility.
• Reliance on discretionary spending, making it vulnerable to economic downturns.

What Could Drive AIRS Stock Higher?

Expansion into new geographic markets, increasing revenue potential.

• Marketing and brand awareness campaigns to attract new customers.
• Development and introduction of new body contouring procedures.
• Strategic partnerships with other healthcare providers.

What Are the Key Risks for AIRS?

Financial-distress signal — its Altman Z-Score of 1.55 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-12.4%) — the business is not currently generating profit on shareholder capital.
• Economic downturns impacting discretionary spending on aesthetic procedures.
• Increased competition from traditional liposuction and other aesthetic services.
• Regulatory changes affecting the body contouring industry.
• Negative publicity or lawsuits related to procedures.
• High beta indicates significant market volatility.

What Are the Growth Opportunities for AIRS?

• Geographic Expansion: AirSculpt has the opportunity to expand its geographic footprint by opening new centers in underserved markets. The market for aesthetic procedures is growing nationally, and strategic expansion into new regions can drive revenue growth. Each new center represents a potential revenue stream, and the company's proven business model can be replicated in new locations. The timeline for opening new centers is dependent on securing suitable locations and obtaining necessary regulatory approvals. Successful expansion requires effective marketing and brand awareness campaigns to attract new customers in each market.
• Service Line Expansion: AirSculpt can expand its service offerings by introducing new procedures and treatments that complement its existing body contouring services. This could include non-surgical skin tightening, cellulite reduction, or other aesthetic treatments. Expanding the service line can attract a broader range of customers and increase revenue per customer. The market for non-surgical aesthetic treatments is growing rapidly, presenting a significant opportunity for AirSculpt. The timeline for introducing new services depends on research and development, clinical trials, and regulatory approvals.
• Marketing and Brand Awareness: AirSculpt can invest in marketing and brand awareness campaigns to attract new customers and increase market share. This could include online advertising, social media marketing, and partnerships with influencers. Increased brand awareness can drive more traffic to AirSculpt centers and increase the number of consultations and procedures. The market for aesthetic procedures is highly competitive, and effective marketing is essential for success. The timeline for implementing marketing campaigns is ongoing, with continuous optimization and adaptation to market trends.
• Technology Innovation: AirSculpt can invest in research and development to further enhance its AirSculpt technology and develop new and improved techniques. This could include advancements in precision, safety, and patient comfort. Technological innovation can differentiate AirSculpt from its competitors and attract customers seeking the most advanced and effective treatments. The market for aesthetic procedures is constantly evolving, and innovation is essential for maintaining a competitive edge. The timeline for technological innovation is long-term, with ongoing research and development efforts.
• Strategic Partnerships: AirSculpt can form strategic partnerships with other healthcare providers, such as dermatologists, plastic surgeons, and medical spas, to expand its reach and referral network. Partnerships can provide access to new customers and markets, and can enhance AirSculpt's credibility and reputation. The market for aesthetic procedures is fragmented, and partnerships can help AirSculpt consolidate its position. The timeline for forming strategic partnerships depends on identifying suitable partners and negotiating mutually beneficial agreements.

What Are AIRS's Competitive Advantages?

• Proprietary AirSculpt technology provides a differentiated service offering.
• Established brand reputation for minimally invasive body contouring.
• Network of strategically located body contouring centers.
• Skilled surgeons and medical staff trained in the AirSculpt procedure.

What Does AIRS Do?

AirSculpt Technologies, Inc., founded in 2012 and headquartered in Miami Beach, Florida, operates as a holding company for EBS Intermediate Parent LLC. The company provides body contouring services, primarily through its patented AirSculpt procedure, a minimally invasive method for removing unwanted fat. AirSculpt distinguishes itself from traditional liposuction by offering a more precise and less invasive approach. The company's services include fat removal from various treatment areas and fat transfer procedures to enhance areas like the breasts, buttocks (Power BBL), and hips (Hip Flip). AirSculpt also offers breast enhancement procedures (Up a Cup). As of March 10, 2022, AirSculpt Technologies operated 19 centers across 15 states, reflecting its expanding geographic footprint within the United States. The company focuses on providing customized body contouring solutions tailored to individual patient needs and preferences. AirSculpt's business model centers around direct-to-consumer marketing and a high-touch patient experience, emphasizing safety and natural-looking results. The company aims to capture a significant share of the growing market for aesthetic procedures by offering a differentiated and patient-centric approach to body contouring.

What Products and Services Does AIRS Offer?

• Provides minimally invasive body contouring services.
• Utilizes the proprietary AirSculpt procedure for fat removal.
• Offers fat transfer procedures to enhance various body areas.
• Operates body contouring centers across multiple states.
• Provides customized treatment plans tailored to individual patient needs.
• Focuses on a direct-to-consumer marketing approach.
• Offers procedures like Power BBL, Up a Cup, and Hip Flip.

How Does AIRS Make Money?

• Generates revenue through fees for body contouring procedures.
• Operates on a direct-to-consumer model, attracting clients through marketing and consultations.
• Employs skilled surgeons and medical staff to perform AirSculpt procedures.

What Industry Does AIRS Operate In?

AirSculpt Technologies operates within the medical care facilities industry, part of the broader healthcare sector. This industry is characterized by increasing demand for aesthetic procedures and a growing focus on minimally invasive techniques. The market for body contouring is expanding, driven by factors such as rising disposable incomes and increasing awareness of aesthetic options. AirSculpt competes with traditional plastic surgery practices and other providers of non-invasive and minimally invasive cosmetic procedures. The company's success depends on its ability to differentiate itself through its proprietary technology, patient experience, and marketing effectiveness. The industry is also subject to regulatory oversight and evolving consumer preferences.

Who Are AIRS's Key Customers?

• Individuals seeking minimally invasive fat removal.
• Patients desiring body contouring and enhancement.
• Consumers looking for alternatives to traditional liposuction.

AirSculpt Technologies, Inc. Financial Trajectory

AirSculpt Technologies, Inc. (AIRS) reported $42.9M in revenue for Q2 2026, reflecting 8.9% growth compared to the prior quarter. The company recorded a net loss of $1.1M, with diluted EPS of $-0.02. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, AIRS averaged $-0.05 in diluted EPS.

Company Profile

AirSculpt Technologies, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Miami Beach, US. The company is led by CEO Yogesh Jashnani. AIRS has traded publicly since 2021.

How AirSculpt Technologies, Inc. Is Valued

AirSculpt Technologies, Inc. carries a market capitalization of $198M, placing it in the micro-cap category. Relative to its peer group, AIRS's quantitative score of 31/100 is below the peer average of 73/100.

Return on equity for AirSculpt Technologies, Inc. stands at -12.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.75 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.2%, the inverse of the P/E and a quick read on earnings relative to price.

AirSculpt Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.55 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project AirSculpt Technologies, Inc. revenue of about $153.2M for fiscal 2026, with EPS near $-0.04.

AIRS Financials

AIRS Latest News

AIRS Analyst Consensus

AIRS MoonshotScore

What Investors Ask About AirSculpt Technologies, Inc. (AIRS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources